一周资源更新 | ASH摘要合集下载；SABCS重点资料整理

ByDrug医药资源云 是聚焦于医药垂直领域的医药信息资源共享中心，其中的资源小站模块主要为关注医药行业的用户提供免费的医药资料文档下载服务。我们将每周1次为大家集中推荐值得收藏的医药资源。更多资源，可以直接通过医药魔方info公众号菜单进入小程序资源小站 检索查阅。

会议报告

第64届美国血液学会（ASH）年会也于本月10日至13日召开，展现了血液学领域的诸多进展。摘要合集如下：

第45届圣安东尼奥乳腺癌研讨会(SABCS)于2022年12月6日至10日在美国圣安东尼奥举行。SABCS重点资料整理如下：

1、ASH 2022 摘要合集

2、SABCS 2022 Trial Assigning IndividuaLized Options for TReatment (TAILORx)_An Update Including 12-Year Event Rates

3、SABCS 2022 Abemaciclib plus endocrine therapy for HR+ HER2- node-positive high-risk early breast cancer_results from a pre-planned monarchE overall survival interim analysis including 4-year efficacy outcomes

4、SABCS 2022 ARV-471_a PROTAC estrogen receptor (ER) degrader in advanced ER-positive HER2- negative breast cancer_phase 2 expansion (VERITAC) of a phase 1or2 study

5、SABCS 2022 Camizestrant a next-generation oral SERD vs fulvestrant in post-menopausal women with advanced ER-positive HER2-negative breast cancer_Results of the randomized multi-dose Phase 2 SERENA-2 trial

6、SABCS 2022 Capivasertib and fulvestrant for patients with aromatase inhibitor-resistant hormone receptor-positive HER2-negative advanced breast cancer_Results from the Phase III CAPItello-291 trial

7、SABCS 2022 EMERALD phase 3 trial of elacestrant versus standard of care endocrine therapy in patients with ER+ HER2- metastatic breast cancer_updated results by duration of prior CDK4or6i in metastatic setting

8、SABCS 2022 PACE_Palbociclib After CDK and Endocrine Therapy_A Randomized Phase II Study of Fulvestrant+-Palbociclib after Progression on CDK4or6 inhibitor for HR+orHER2- Metastatic Breast Cancer

9、SABCS 2022 Pregnancy Outcome and Safety of Interrupting Therapy for women with endocrine responsIVE breast cancer Initial Results from the POSITIVE Trial (IBCSG 48-14_BIG 8-13_Alliance A221405)

10、SABCS 2022 Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer_Updated results of the randomized, phase 3 study DESTINY-Breast03

11、SABCS 2022 Trastuzumab deruxtecan vs physician’s choice in patients with HER2+ unresectable and or metastatic breast cancer previously treated with trastuzumab emtansine_Primary results of the randomized phase 3 study DESTINY-Breast02

公司资料

本周，诺华，武田，安进，Cytokinetics都发布了其相关产品的公司演讲。具体如下：

1、ASH 2022 诺华 Iptacopan information

2、Takeda to Acquire Late-Stage_Potential Best-in-Class_Oral Allosteric TYK2 Inhibitor NDI-034858 From Nimbus Therapeutics

3、Amgen to Acquire Horizon Therapeutics

4、Omecamtiv Mecarbil information from FDA

5、Omecamtiv Mecarbil information from Adcomm

6、礼来 2023 Guidance presentation